Premium
The effect of some commercially available antihistamine and decongestant intra–nasal formulations on ciliary beat frequency
Author(s) -
Su X. Y.,
Po A. Li Wan
Publication year - 1993
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/j.1365-2710.1993.tb00617.x
Subject(s) - oxymetazoline , azelastine , antihistamine , decongestant , nasal decongestant , medicine , nasal administration , ephedrine , anesthesia , pharmacology , nasal spray , adrenergic receptor , receptor
SUMMARY The effects of azelastine (0.1%) nasal spray (Rhinolast®) on ciliary beat frequency are investigated and. compared with those of oxymetazoline hydrochloride (Vicks Sinex®), xylometazoline (Otrivine®) and ephedrine hydrochloride (0.5%). It is shown that all four formulations exert a ciliotoxic effect. The antihistamine (azelastine) and the two long–acting α sympathomimetic decongestants (xylometazoline and oxymetazoline) had comparable effects which were milder than those observed with ephedrine, the less specific α and β sympathomimetic agent. The results suggest that the intranasal application of all four products should be restricted to short–term therapy. Oral antihistamine therapy and not topical therapy should still be the first–line therapy for antihistamine–responsive rhinitis until non–ciliotoxic formulations can be developed.